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Summary In the present study, the expression of the epidermal growth factor receptor (EGFR) was
investigated in putative preneoplastic and neoplastic acinar cell lesions induced in the rat pancreas by azaserine,
using Northern blotting, in situ hybridisation (ISH) and immunohistochemistry. EGFR protein levels were
decreased in putative preneoplastic eosinophilic acinar cell lesions (atypical acinar cell nodules, AACN) in
comparison with normal acinar cells of the pancreas. However, EGFR mRNA expression correlated positively
with the volume of AACN in pancreatic homogenates and ISH showed equal or stronger EGFR mRNA
expression in AACN than in the surrounding normal acinar cells. Neither EGFR protein nor EGFR mRNA
was detected in more advanced lesions such as acinar adenocarcinomas (in situ). Moreover, EGFR protein
expression showed an inverse relationship with the mitotic rate of the acinar cells. These findings suggest that
down-regulation of EGFR at the protein level may abrogate negative constraints on cell growth, which may
stimulate the development of putative preneoplastic AACN to more advanced lesions and, ultimately, acinar
adenocarcinomas.
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Despite an increasing number of advanced diagnostic
techniques and new therapies, the 5 year survival rate of
patients with tumours of the exocrine pancreas is not more
than 3% (Warshaw and Castillo, 1992). This poor prognosis
is mainly due to late diagnosis and the absence of effective
therapeutic modalities. Therefore, there is a need for studies
on pancreatic cancer that concentrate on the detection of
modulating factors involved early in the carcinogenic process.
As originally proposed by Temin (1966), one of the causes of
the uncontrolled proliferative character of tumours might be
inappropriate autocrine or paracrine production of growth
factor (receptor)s (Lang and Burgess, 1990). The epidermal
growth factor receptor (EGFR) is believed to be one of these
factors (Elder, 1994). In non-transformed (normal) cells,
EGFR expression generally appears to be regulated within a
rather narrow range of 20 000-100 000 receptors per cell
(Velu, 1990). In both normal and transformed keratinocytes,
EGFR expression is regulated at several levels, including
transcription, mRNA stability, translation and post-transla-
tional modification (Pas et al., 1991). In certain tumour cell
lines, such as the A431 epidermoid carcinoma cell line,
EGFR mRNA and protein levels are markedly increased as a
result of amplification of the EGFR gene (Merlino et al.,
1984). EGFR is also overexpressed in several human
pancreatic cancer cell lines (Korc et al., 1986; Gamou et
al., 1984), as well as in the pancreas of patients with
pancreatic cancer and chronic pancreatitis (Lemoine et al.,
1992; Smith et al., 1987). Overexpression of EGFR in human
pancreatic tumours has been associated with an autocrine cell
growth stimulation cycle (Lemoine et al., 1992; Smith et al.,
1987; Korc et al., 1992). Furthermore, the v-erbB proto-
oncogene of the avian erythroblastosis virus encodes a
protein resembling EGFR (Downward et al., 1984),
supporting the oncogenic potential of EGFR.
In the present study, the expression of EGFR was
characterised in putative preneoplastic atypical acinar cell
lesions (AACN) and in acinar tumours induced in rat
pancreas by azaserine (Longnecker, 1983; Scherer et al.,
1989). EGFR mRNA expression was determined and
quantified by Northern blotting, whereas the localisation of
EGFR mRNA in the pancreas was determined by in situ
hybridisation. Furthermore, EGFR distribution at the
protein level was determined by immunohistochemistry and
was correlated with the proliferating cell nuclear antigen
(PCNA=proliferation marker) expression in the pancreas.
Materials and methods
Pancreas isolation
To induce pancreatic carcinogenesis, 35 albino Wistar WU
rats (Charles River Wiga, Sulzfeld, Germany) were injected
intraperitoneally at 14 and 21 days of age with 30 mg
azaserine (Calbiochem-Bering, La Jolla, CA, USA) per kg
body weight according to an injection protocol described
previously (Woutersen et al., 1989). Ten rats were injected
with saline instead of azaserine and served as untreated
controls. All animals were housed under similar standard
conditions. The rats were killed 15 months after the last
injection with azaserine. The animals were anaesthetised with
ether, exsanguinated by cannulating the abdominal aorta and
then examined for gross pathological changes. The entire
pancreas was excised. Grossly visible pancreatic tumours
were separated from normal pancreas and portions of both
tissues were frozen and stored in liquid nitrogen immediately
after dissection, or fixed in 4% buffered formalin and
routinely embedded in paraffin wax.
Histology
At three different levels, ten 5,um serial sections were
prepared from the paraffin embedded pancreata obtained
from treated and untreated rats. One section from each level
was stained with haematoxylin and eosin (H&E) and
examined by light microscopy. Likewise, one part of the
liquid nitrogen frozen pancreas was used for preparation of
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cryostat sections and the adjacent part was used for the
molecular biological techniques. The cryostat sections were
fixed for 10 min in 4% buffered formalin, stained routinely
with H&E and examined by light microscopy (Scherer et al.,
1989). Based on the results of the microscopical examina-
tions, directly adjacent parts of the same tissues were selected
for further experiments (such as Northern blotting), defined
as having either normal, preneoplastic or tumorous histology.
Immunohistochemistry
Two different mouse monoclonal antibodies were used to
detect EGFR immunoreactivity in paraffin-embedded pan-
creas sections obtained from all untreated control rats and
from more than 20 azaserine-treated rats. At least two
sections from every individual rat were incubated. One
antibody was a generous gift from Dr WA Dunn, University
of Florida, diluted 1:100 and earlier proved to be suitable for
immunohistochemical localisation of EGFR in rat tissue
(Simms et al., 1991), the other EGFR antibody was
purchased from Sigma (St. Louis, MO; clone 29.1), diluted
1:2000. Both antibodies were directed to the extracellular
domain of EGFR (Chandler et al., 1985), but are most
probably directed against different epitopes, since the
antibody from Dr Dunn was reported to interfere with
EGF binding to the EGFR, whereas the Sigma antibody does
not interfere with this ligand-receptor binding. To demon-
strate differences in mitotic rate, the proliferation marker
PCNA (proliferating cell nuclear antigen; Santa Cruz
Biotechnology, CA, USA; dilution 0.2 sg ul-') was detected
on parallel sections. After deparaffinisation, endogenous
peroxidase activity was quenched by incubation 0.6%
hydrogen peroxide in methanol for 30 min. The sections
were pretreated with 0.3% Triton X-100 in phosphate-
buffered saline (PBS, 0.14 mm sodium chloride; 8.93 mM
disodium hydrogen phosphate; 1.28 mm sodium dihydrogen
phosphate; pH 7.4) for 15 min. The slides were incubated for
2 h with the first antibody in 2% bovine serum albumin
(BSA) in PBS in a humid slide chamber. To detect the
monoclonal antibody, subsequent peroxidase-conjugated
rabbit anti-mouse antibody and peroxidase-conjugated swine
anti-rabbit antibody (RAMPO/SWARPO; Dako, Glostrup,
Denmark; duluted 1:100) incubations were performed. Both
RAMPO and SWARPO were diluted in PBS containing 10%
normal rat serum and incubated for 30 min. Between each
incubation step the sections were washed three times for
5 min with PBS-Tween (0.05%), with the exception of the
last washing step where Tween was omitted. Subsequently, a
brown precipitate could be observed by light microscopy
after the peroxidase reaction with 3,3'-diaminobenzidine
tetrahydrochloride (DAB; Sigma). The sections were counter-
stained with Mayer's haematoxylin. Expression of EGFR in
this study is defined as staining of cell membranes, often
accompanied by cytoplasmic staining.
RNA isolation
Total RNA was isolated by a modification of the procedures
described by Chomczynski and Sacchi (1987) and Chirgwin et
al. (1979). Standard precautions were taken to prevent
contamination of solutions and glasswork with RNAases
(Sambrook et al., 1989). RNA was isolated from parts of
total pancreas and from the grossly visible pancreatic
adenocarcinomas isolated at final autopsy. Unfortunately,
because of the extremely high RNAase content in rat
pancreas, in combination with the relatively long time
needed to dissect out the small, but macroscopically visible
preneoplastic lesions, it appeared to be impossible to isolate
good quality RNA from these small lesions. Therefore, effects
on RNA levels in preneoplastic lesions were only detected in
total pancreas homogenates containing both 'normal' tissue
and lesions. Frozen tissue samples (0.1-0.3 g) were homo-
genised in a high-speed homogeniser (Ultra Turrax; Janke
and Kukel-IKA, Staufen, Germany: 15-20 s at 25 000
r.p.m.) in 3 -5 ml of GuSCN (4 M guanidium thiocyanate;
1% fl-mercaptoethanol, 0.5% N-lauroylsarkosine; 25 mM
sodium citrate). RNA was separated from DNA and
proteins by ultracentrifugation at 40 000 r.p.m. overnight
through a 5.7 M caesium chloride cushion or by acid-
phenol-chloroform extraction and subsequent precipitation
at -20°C with 0.025 volume 1 M acetic acid and 0.5 volume
ethanol. After removing the supernatant, the RNA pellet was
redissolved in 800 ,l GuSCN. RNA was precipitated again
with 0.025 volume 1 M acetic acid and 0.6 volume ethanol.
Finally, the RNA pellet was washed in 70% ethanol, dried
for 5-10 min in a Speedvac (SVC1OOH; Savant, Farming-
dale, NY, USA), and redissolved in diethylpyrocarbonate
(DEPC)-treated water. Quantity and quality of the RNA
were monitored by spectrophotometry at 260 nm and 1%
agarose gel electrophoresis respectively.
Northern blotting
A sample of 25 Mg total RNA was denatured in sample buffer
(10 x MOPS-37% formaldehyde-formamide=2:3:10) for
5 min at 65°C, and separated by size on a 1.2% denaturating
gel for 4-5 h. Ethidium bromide was added to the RNA
sample just before loading of the gel. Equality and integrity
of RNA loading was checked by examining ethidium
bromide staining intensities of the ribosomal bands. RNA
was transferred to a nylon membrane and cross-linked by UV
Prehybridisation and hybridisation were performed overnight
at 65°C. Typically, 0.5-1 x 106 c.p.m. ml-1 of the 32P-labelled
rat EGFR riboprobe was used for hybridisation in the
presence of hybmix (50% formamide; 0.4% sodium dodecyl
sulphate(SDS); 4 x SSC; 4 x Denhardt's; 0.2 mg ml-1 ssDNA;
0.04 M sodium phosphate pH 7.4; 10% dextran sulphate).
Blots were washed twice at low stringency (1 x SSPE; 0.5%
SDS; 15 min at 65°C) and once or twice at high stringency
(0.1 x SSPE; 0.5% SDS; 15 min at 65°C). The blots were
exposed to a phosphor storage screen for 2 days and
subsequently scanned by a phosphorimager (Personal
Densitometer, Molecular Dynamics, Sunnyvale, CA, USA).
A total of 22 pancreatic RNA samples obtained from 17
different rats [four untreated controls (pancreata without any
lesions), 12 azaserine-treated rats (pancreata with preneo-
plastic lesions and five macroscopically isolated acinar
adenocarcinomas)] were used for quantification of EGFR
mRNA levels. Only RNAs from one isolation blotted on one
individual membrane showing equally bright ribosomal bands
and equal amount of degradation on the original agarose gel
were used for quantitative comparisons. This approach
resulted in four independent Northern blots to be used for
quantification. EGFR mRNA levels were calculated as
percentages of 7S RNA (detected with a 7S-specific DNA
probe, Balmain et al., 1982) using the computer program
ImageQuant (Molecular Dynamics), and subsequently
statistically correlated with the number of lesions observed
in parallel sections.
In situ hybridisation
Duplicate, 5 Mm-thick, formalin-fixed, paraffin-embedded
tissue sections from two untreated controls and two
azaserine-treated rats were placed on poly-L-lysine
(1 mg ml-') coated glass slides, and subsequently deparaffi-
nised, hydrated, permeabilised with 1 Mg ml-' proteinase K
(Boehringer Mannheim) for 10 min at 37°C, and prehybri-
dised in hybridisation buffer (50% formamide, 20 mM Tris-
HCl pH 8.0, 5 mM EDTA, 1 xDenhardt's, 5% dextran
sulphate, 10 mM dithiothreitol, 0.3 M sodium chloride) for
4 h at 42°C. As a negative control for mRNA hybridisation,
the sections were treated with 200 Mg ml-' RNAase A,
10 U ml-1 RNAase TI for 1 h at 37°C just before
prehybridisation. As positive controls, hybridisations have
been performed with probes directed against insulin.
Hybridisation was performed overnight at 50°C with
2.5x 105 c.p.m. of 33P-labelled rat EGFR riboprobe andEGFR in pancreatic carcinogenesis
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1 MI of tRNA (50 jug pul-1) in 200 ,ul of hybridisation buffer
per slide. After hybridisation, non-bound probe was digested
with RNAase A (Boehringer Mannheim, 20 jig yl-') for
30 min at 37°C, and aspecific binding was washed with
increasing stringency. The sections were coated with
autoradiography emulsion (Eastman Kodak, Rochester,
NY, USA) and exposed for 5-10 days. The sections were
developed and fixed and subsequently counterstained with
haematoxylin.
Preparation of the rat EGFR riboprobe
The rat EGF receptor cDNA fragment, corresponding to
nucleotide bases 249-951 (Petch et al., 1990) was amplified
by PCR from reverse-transcribed rat liver RNA using PCR
primers which contained unique BamHI and SphI restriction
sites. The PCR products were generated in 40 cycles (94°C,
1.5 min; 42°C, 1.5 min; and 72°C, 1.5 min), subsequently
subcloned into a pGEM7Zf vector (Promega), and authen-
ticity was confirmed by sequencing.
Results
Immunohistochemistry
In the normal rat pancreas, immunohistochemical studies
with monoclonal antibodies directed to the EGFR demon-
strated expression in the cytoplasm of acinar cells, sometimes
with accentuation of the cell membranes (Figure 1). Both
anti-EGFR monoclonal antibodies gave similar staining
patterns in all tissue sections that were investigated.
Pancreatic cells of rats not treated with azaserine showed
similar staining patterns to histologically normal pancreatic
cells of rats that were treated with azaserine. No differences
in EGFR staining intensities were observed in non-pancreatic
cells (such as vascular endothelial cells, macrophages or nerve
fibres) when comparing azaserine-treated with untreated rats.
Ductular and endocrine cells were negative. Surprisingly,
normal acinar cells stained more intensely for EGFR than the
eosinophilic acinar cells of putative preneoplastic atypical
acinar cell lesions (AACN; Figures 1 and 2). More advanced
lesions such as nodules-in-nodules (Figure 3a), carcinomas in
situ and acinar adenocarcinomas were negative. The AACN
exhibited a large variation in their intensity of EGFR
immunoreactivity (Figure 2), which was found predomi-
nantly in the cytoplasm in these lesions since hardly any
immunoreactivity to EGFR was present on the cellular
membranes. The AACN also varied in number of cells with
immunoreactivity to EGFR. In some lesions only a few
dispersed cells were positive, whereas other lesions showed an
almost similar immunoreactivity to EGFR as the surround-
ing normal acinar cells. Figure 2 demonstrates clearly the
variance in EGFR immunoreactivity within one pancreas
tissue section, ranging from hardly any staining through a
staining intensity similar to normal acinar cells. In general,
larger (more advanced) atypical acinar cell lesions, when
Figure 2 Immunohistochemical localisation of EGFR in
azaserine-treated rat pancreas. Note differences in intensities of
EGFR in the putative preneoplastic lesions. P, putative
preneoplastic atypical acinar cell nodule. The antibody used is
MAb 29.1 (Sigma); bar=400 im.
Figure 1 Immunohistochemical localisation of EGFR in Figure 3 Immunohistochemical localisation of (a) EGFR and (b)
azaserine-treated rat pancreas. I, islet of Langerhans cells; A, PCNA, in azaserine-treated rat pancreas. A, normal pancreas
normal pancreas acinar cells; P, putative preneoplastic atypical acinar cells; P, putative preneoplastic atypical acinar cell nodule
acinar cell nodule; arrowheads point to membranous staining. (primary lesion); N, nodule-in-nodule (secondary lesion). The
The antibody used is MAb 29.1 (Sigma); bar= 50,um. antibody used is MAb 29.1 (Sigma); bar= 200 im.EGFR in pancreatic carcinogenesis
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loosing their typical nodular (circular) shape, also lost their
EGFR immunoreactivity. However, no obvious variations in
staining patterns could be observed between the pancreatic
sections of different rats.
Immunohistochemical detection of the proliferation
marker PCNA in parallel sections clearly demonstrated an
inverse relationship between mitotic rate and immunoreactiv-
ity to EGFR (Figure 3b). In contrast with the putative
preneoplastic eosinophilic atypical acinar cell foci, the
basophilic atypical acinar cell foci (which are not considered
to be preneoplastic) could not be distinguished from normal
acinar cells by incubation with either the anti-EGFR
antibodies or the PCNA antibody (not shown). Sections of
the rat submaxillary and sublingual salivary glands were used
as controls for the specificity of the anti-EGFR antibodies.
As expected, strong immunoreactivity was apparent only on
the serous cells. Omitting the anti-EGFR or anti-PCNA first
antibodies resulted in complete absence of staining.
Northern blotting
A total of 17 rat pancreatic tissues comprising normal and
putative preneoplastic acinar cells, and five macroscopically
isolated acinar adenocarcinomas were analysed by Northern
blotting (Figure 4). No differences in EGFR mRNA
expression were observed in homogenates from untreated
controls or from rats treated with azaserine with no, or a
very low number of AACN in their pancreas (observed in
parallel sections from the pancreatic pieces used for
homogenisation). A significantly positive correlation was
found for the EGFR mRNA levels when compared with
the number of atypical acinar cell lesions found in parallel
sections from the same pancreata (four independent Northern
blots: r=0.9950, P<0.05; r=0.9993, P<0.01; r=0.85263;
P<0.05; r=0.9953, P<0.05). However, no EGFR mRNA
expression was detected by Northern blotting on total RNA
from the isolated acinar adenocarcinomas, whereas ethidium
bromide staining intensity and 7S control signal were equally
detectable (Figure 4).
< EGFR
<28S
< 18S
<7S
1 2 3
Figure 4 EGFR mRNA levels detected by Northern blotting in
pancreatic homogenates from azaserine-treated rats. The blots
were rehybridised with a 7S cDNA probe in order to quantify
RNA loading. Lane 1, normal pancreas; lane 2, preneoplastic
pancreas; lane 3, acinar adenocarcinoma. 28S, 18S, location of the
ribosomal subunits.
In situ hybridisation
Hybridisation of rat pancreas sections with the 33P-labelled
rat EGFR riboprobe revealed a positive signal in the acinar
cells of normal pancreas, whereas no grains could be
observed in the ductular (Figure 5a, exposure time 10 days)
and endocrine cells (not shown). Furthermore, putative
preneoplastic atypical acinar cell nodules exhibited a similar
number or even more grains than the normal acinar cells
(Figure 5b, exposure time 5 days). However, in more
advanced lesions (e.g. carcinoma in situ), EGFR mRNA
was only faintly detectable (Figure 5c, exposure time 10 days)
or undetectable. When the sections were pretreated with
RNAase, no differences in signals were observed between
normal, preneoplastic or neoplastic tissues; the few remaining
grains were considered to represent background (Figure 5d,
exposure time 10 days).
Discussion
Using immunohistochemistry, Northern blotting, and in situ
hybridisation, the present study clearly demonstrates that
epidermal growth factor receptors (EGFRs) are detectable on
pancreatic acinar cells of normal rats and of rats treated with
azaserine, as summarised in Table I. By Northern blotting,
the presence of a high number of putative preneoplastic
atypical acinar cell nodules (AACN) was associated with
increased expression of EGFR mRNA compared with
pancreatic tissues containing no or a low number of
AACN. In contrast, by immunohistochemistry, most AACN
exhibited decreased EGFR immunoreactivity, indicating a
decrease in the amount of EGFR protein. The discordance
between EGFR mRNA and protein levels could be due to
inhibition of EGFR at the translational level, increased
EGFR protein degradation or shedding of EGFR by the
AACN cells. Another explanation could be that up-
regulation of EGFR in putative preneoplastic acinar
pancreatic cells of rats contributes to cell proliferation, but
that a high degree of receptor signalling and turnover within
the lesion results in a relatively low level of observable
receptor protein at any point of time.
EGFR was not detectable in acinar adenocarcinomas by
either immunohistochemistry, in situ hybridisation or North-
ern blotting, indicating that in advanced acinar lesions,
transcription of DNA coding for EGFR either does not take
place or EGFR mRNA is markedly and rapidly degraded.
These findings suggest that EGFR may not play an essential
role in the pancreatic carcinogenic process in azaserine-
treated rats. Alternatively, EGFR may be involved in the
regulation of differentiated functions in the rat pancreatic
acinar cell and may exert growth-suppressive effects on this
cell type.
It cannot be excluded that diminished EGFR immunor-
eactivity as observed in the present study is the result of a
change of the epitope instead of actual decrease in the
number of EGFR present. However, this explanation does
not seem to be very likely, since we found similar results with
two different monoclonal antibodies directed to the EGFR.
Moreover, it has been established that the antibodies used are
reactive in rats since they demonstrate a positive reaction
with salivary glands collected from the same animals.
It is conceivable that the findings presented in this paper
are typical for acinar pancreatic cells only and may very well
not apply for ductular pancreatic cells or ductular
adenocarcinomas of the pancreas. To our knowledge, human
acinar adenocarcinomas have not been investigated for the
presence of EGFR. Similar experiments to those described in
this paper are performed in our Institute with N-nitrosobis(2-
oxopropyl)amine-treated hamsters as a model for ductular
adenocarcinomas (Pour and Wilson, 1980), in order to
investigate whether EGFR might play a role in the
development of pancreatic ductular carcinomas.
Decreased EGFR-mediated signalling may thus lead toEGFR in pancreatic carcinogenesis
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Figure 5 EGFR mRNA detection by in situ hybridisation in azaserine-treated rat pancreas. (a) A, acinar cells; D, ductular cells. (b)
A, acinar cells; P, putative preneoplastic atypical acinar cell nodule. (c) A, normal pancreas acinar cells; C, adenocarcinoma. (d)
after RNAase treatment; A, normal pancreas acinar cells; P, putative preneoplastic atypical acinar cell nodule. Differences in signal
intensities between sections are due to differences in exposure times; bar= 50,m.
Table I Summary of the results obtained from pancreatic acinar
cells of azaserine-treated ratsa
EGFR protein EGFR mRNA PCNA
Phenotype (IHC) (ISH, North.) (IHC)
Normal + + ±
Putative preneoplastic + +/+++ + +
Neoplastic + +
aThe values are based on microscopic examinations of pancreatic
acinar cells or densitometrical data as indicated in the text. Values are
relative levels in the different tissue types: -, not present; i,
moderately present; +, clearly present; + +, strongly present; IHC,
immunohistochemistry; ISH, in situ hybridisation; North., Northern
blotting; EH, enzyme histochemistry.
loss of differentiated functions and increased propensity
toward neoplastic transformation. Indeed, several lines of
evidence suggest an anti-mitogenic role for EGFR in the rat
exocrine pancreas. First, the rat pancreatic acinar cell has
specific high-affinity EGF receptors (Korc et al., 1983), and
EGF is necessary for the maintainance of this cell type in
serum-free culture (Brannon et al., 1985). Second, EGF
enhances rat acinar cell survival and pancreatic protein
synthesis at concentrations as low as 42 pM (Brannon et al.,
1985; 1986; 1988). Third, this action of EGF is relatively
specific, inasmuch as a similar effect occurs only at 2.7 nM
IGF-1 and does not occur with insulin (Brannon et al., 1988).
Fourth, EGF decreases thymidine incorporation into
pancreatic DNA in male, Sprague-Dawley rats (Morisset
et al., 1989) and increases pancreatic content of amylase and
chymotrypsinogen while preventing caerulein-mediated de-
sensitisation of the acinar cell secretory responsiveness
(Morisset et al., 1989). Fifth, EGF binding is decreased in
the regenerating rat pancreas following 90% pancreatectomy,
in parallel with an increase in acinar cell mitotic activity
(Brockenbrough et al., 1988). Sixth, the results of a recent
study performed by our group demonstrated that putative
preneoplastic atypical acinar cell lesions may develop into
acinar adenocarcinomas independently of TGF-az or EGF
(Visser et al., 1995). Thus, a decrease in EGFR-mediated
signalling in the rat pancreatic acinar cell may lead to
enhanced carcinogenesis.
However, another explanation could be that cells within
the neoplastic lesion may have accumulated other genetic
alterations e.g. in other members of the EGFR family, such
as c-erbB-2 (HER-2, ERBB2, neu; Yamamoto et al., 1986;
Coussens et al., 1985; Stern et al., 1986) or ERBB3 (Kraus et
al., 1989; Plowman et al., 1990), driving cell division without
the necessity for EGFR signalling. Consequently, the EGFR
gene is generally switched off in the malignant adenocarci-
noma cells.EGR i c
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Abbrhtoa
AACN, atypical acinar cell nodules; EGF(R), epidermal growth
factor (receptor); ISH, in situ hybridisation; mRNA, messenger
RNA; PCNA, proliferating cell nuclear antigen; RAMPO,
peroxidase-conjugated rabbit-anti-mouse antibody; SWARP,
peroxidase-conjugated swine anti-rabbit antibody.
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